Hepatocellular carcinoma (HCC) is a prevalent disease in Asia and the second leading cause of cancer death in Hong Kong.1 Surgical resection is regarded as the curative treatment. However, only 20% to 30% of HCC patients are suitable surgical candidates.2,3 Over the years, various locoregional therapies have been employed for the treatment of unresectable HCC. These include the widely practised...

Reprint requests to: Dr. Jiunn-Ming Lii Department of Radiology, Taipei City Hospital. No. 10, Sec. 4, Ren Ai Road, Taipei 106, Taiwan, R.O.C. Hepatic hemangiomas are not routinely treated except for large symptomatic lesions. Transarterial chemo-embolization (TACE) and percutaneous ethanol injection (PEI) are often used to treat hepatocellular carcinoma (HCC). We report a patient with underlyi...

The liver is the second only to lymph nodes as the most common site of metastatic disease irrespective of the primary tumor. Up to 50% of all patients with malignant diseases will develop liver metastases with a significant morbidity and mortality. Although the surgical resection leads to an improvement of the survival time, only approximately 20% of the patients are eligible for surgical inter...

BACKGROUND AND AIMS Percutaneous tumour ablation (PTA), such as ethanol injection and radiofrequency ablation, is now recognised as a primary treatment for hepatocellular carcinoma (HCC). Although PTA is a relatively safe procedure, it can cause biliary obstruction as a rare complication. As patients with cirrhosis undergoing surgery or endoscopic retrograde cholangiopancreatography/sphincterot...

Hepatocellular carcinoma (HCC) is the sixth most common cancer in the world and the third most common cause of cancer-related death (Benson et al., 2009). Hepatic resection is still to get the possibility of cure for patients with HCC, but majority of patients diagnosed with HCC have loose surgery opportunity (Hsu et al., 2011). Radiofrequency ablation (RFA), percutaneous ethanol injection (PEI...

Despite advances in current treatment options, Hepatocellular Carcinoma (HCC) recurrence still presents as a significant clinical challenge. After initial treatment, HCC occurs considerable portion of patients without an available standardized protocol for managing such incident. Recurrence advanced liver disease may make surgical options impossible, which case, locoregional therapy should be c...

The incidence of primary liver cancer in Canada has been steadily increasing, having more than doubled since 1980.1 This increase is partially attributed to the increasing rates of hepatitis C infection, alcohol abuse, and immigration from developing countries where the incidence of hepatocellular carcinoma (HCC) is much greater.1,2 The liver is also the most common site of metastases, especial...

BACKGROUND We evaluated treatment modalities and survival in patients with hepatocellular carcinoma (HCC), by pre-treatment and 3-month post-treatment serum alpha-fetoprotein (AFP) levels and pre-treatment tumor diameters. METHODS We retrospectively reviewed 57 patients treated for HCC in our department from January 2002 to December 2012, including their sex, type of hepatitis, Child class, p...